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ABSTRACT
CONTEXT AND OBJECTIVE: Graft-versus-host disease (GVHD) is one of the complications following allo-
genic stem cell transplantation. This study investigated an association between human leukocyte antigen 
(HLA) and the occurrence of acute and chronic GVHD in patients who had received stem cell transplanta-
tions from HLA-identical siblings. 
DESIGN AND SETTING: Retrospective study at Hematology and Hemotherapy Center, Universidade Es-
tadual de Campinas (Unicamp). 
METHODS: The participants were 176 patients whose first transplant was between 1997 and 2009. HLA 
genotyping was performed serologically and using the polymerase chain reaction with specific primer 
sequence.  
RESULTS: Acute GVHD was positively associated with HLA-A10 (P = 0.0007), HLA-A26 (P = 0.002), B55 
(P = 0.001), DRB1*15 (P = 0.0211) and DQB1*05 (P = 0.038), while HLA-B16 (P = 0.0333) was more frequent 
in patients without acute GVHD. Chronic GVHD was positively associated with HLA-A9 (P = 0.01) and 
A23 (P = 0.0292) and negatively with HLA-A2 (P = 0.0031) and B53 (P = 0.0116). HLA-B35 (P = 0.0373), 
B49 (P = 0.0155) and B55 (P = 0.0024) were higher in patients with acute GVHD grade 3 or above, than in 
other patients. In patients with extensive chronic GVHD, HLA-A9 (P = 0.0004), A24 (P = 0.0059) and A26 
(P = 0.0411) were higher than in other patients, while HLA-A2 was lower (P = 0.0097). 
CONCLUSION: This study suggests that HLA can influence the incidence and severity of acute and chronic 
GVHD. However, a study with a better design and more patients will be needed to confirm these results. 
RESUMO
CONTEXTO E OBJETIVO: A doença do enxerto contra o hospedeiro (DECH) é uma das complicações pós-
transplante alogênico de células progenitoras hematopoéticas. Este estudo investigou uma associação 
entre o antígeno leucocitário humano (HLA) e a ocorrência de DECH aguda e crônica, em pacientes que 
receberam transplantes de irmãos HLA-idênticos. 
TIPO DE ESTUDO E LOCAL: Estudo retrospectivo no Centro de Hematologia e Hemoterapia da Universi-
dade Estadual de Campinas (Unicamp). 
MÉTODOS: Os participantes foram 176 pacientes cujo primeiro transplante foi entre 1997 e 2009. A tipa-
gem HLA foi realizada por sorologia e reação em cadeia da polimerase (PCR) com sequência específica 
de primers.
RESULTADOS: A DECH aguda foi associada positivamente com HLA-A10 (P = 0,0007), HLA-A26 (P =  0,002), 
B55 (P = 0,001), DRB1*15 (P = 0,0211) e DQB1*05 (P = 0,038), enquanto HLA-B16 (P = 0,0333) foi mais 
frequente em pacientes sem DECH aguda. A DECH crônica foi associada positivamente com HLA-A9 
(P = 0,01) e A23 (P = 0,0292) e, negativamente, com HLA-A2 (P = 0,0031) e B53 (P = 0,0116). HLA-B35 
(P = 0,0373), B49 (P = 0,0155) e B55 (P = 0,0024) estavam aumentados em pacientes com DECH aguda 
grau 3 ou maior, em comparação aos outros pacientes. Em pacientes com DECH crônica extensa, HLA-A9 
(P = 0,0004), A24 (P = 0,0059) e A26 (P = 0,0411) estavam aumentados em comparação aos outros pacien-
tes, enquanto HLA-A2 estava diminuído (P = 0,0097). 
CONCLUSÕES: Este estudo sugere que o HLA pode influenciar a ocorrência de DECH aguda e crônica e 
a sua gravidade. No entanto, um estudo com melhor desenho e com mais pacientes será necessário para 
confirmar esses resultados.
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INTRODUCTION
Graft-versus-host disease (GVHD) remains an important source 
of morbidity and mortality following allogenic hematopoietic 
stem cell transplantation (HSCT). Although susceptibility to this 
complication has been shown to be influenced by the immuno-
genetic background of the donor/recipient pair,1,2 the potential 
impact of human leukocyte antigen (HLA)-like genes on HSCT 
outcomes remains poorly explored.
Under these circumstances, donor T-cell recognition of host 
HLA can give rise to GVHD, and host recognition of donor HLA 
may increase the risk of graft failure. Identifying GVHD risk 
factors may help to reduce its incidence and severity. Previous 
reports have suggested that particular HLA system factors have 
an impact on GVHD3-11 and give rise to a reduced relapse rate 
and improved survival after HSCT.12
HLA molecules are the most important immunogenic proteins 
contributing towards the intensity of the GVHD reaction.13 Class I 
antigens (HLA-A, -B and -C) and Class II antigens (DR, DQ and 
DP) are the classical molecules in the major histocompatibility com-
plex (MHC), which are encoded by MHC in chromosome 6. HLA 
antigens from host tissues are recognized by donor T cells that are 
critical for the development of both acute and chronic GVHD.
To our knowledge, in Brazil, there have not been any studies 
investigating an association between HLA and GVHD develop-
ment. Consequently, there is intense interest in defining the best 
HLA genetic markers for allogenic HSCT outcomes and incor-
porating these into routine donor selection strategies in the Bra-
zilian population.
OBJECTIVE 
The objective of this study was to investigate an association 
between HLA and the occurrence of acute and chronic GVHD in 
patients who had received stem cell transplantation from HLA-
identical siblings in a Brazilian population. 
PATIENTS AND METHODS
Study design and data collection
The clinical records of allogenic HSCT recipients in one hematol-
ogy and hemotherapy center were retrospectively reviewed and 
176 patients who had received a first matched-sibling allogenic 
HSCT between 1997 and 2009 were found. These patients were 
followed up to ascertain their clinical outcomes up to the cutoff 
point of June 2010. The characteristics of the study population 
are presented in Table 1.
Only patients who developed acute GVHD or survived 
for more than 100 days without GVHD, and were therefore at 
risk of developing acute GVHD, were included in the analyses 
for acute GVHD. For chronic GVHD, patients who had devel-
oped chronic GVHD or survived for more than 110 days without 
chronic GVHD were included.
All of the patients and donors were residents of Campinas 
and the surrounding region in the State of São Paulo and were 
classified as a mixed population due to their genetic background 
of European, African and Amerindian origin. 
This study was conducted in accordance with the guidelines 
of the Ethics Committee of the University Hospital of Universi-
dade Estadual de Campinas (Unicamp).
GVHD assessment
Occurrences of GVHD were classified in accordance with Glucks-
berg et al.14 and Atkinson et al.15 In our study, we classified grades 
0 to II as mild acute GVHD and grades III to IV as severe acute 
GVHD. Chronic GVHD was considered to be severe when it was 
classified as extensive.
HLA genotyping
HLA matching was performed serologically for HLA-A and -B 
antigens (One Lambda, Canoga Park, CA, USA), and for HLA-
DRB1 and -DQB1 using molecular typing (Dynal sequence-spe-
cific primer, Dynal Ltd., Bromborough, Wirral, UK; One Lambda, 
Canoga Park, CA, USA).
Statistical analysis
Screening for associations between HLA-A, HLA-B, HLA-DRB1 
and DQB1 variants and GVHD incidence was carried out using 
chi-square statistics with Yates correction or Fisher’s exact test when 
needed. Odds ratios (OR) with 95% confidence intervals (95% CI) 
were also calculated. P values < 0.05 were considered statistically 
significant, but to account for multiple comparisons, the observed 
Characteristic
Average patient age in years (range) 34.0 (1-60)
Average donor age in years (range) 32.0 (1-62)













Source of cells - n (%)
Bone marrow 104 (59.1%)
Peripheral blood stem cell 72 (40.9%)
Table 1. Characteristics of the study population (n = 176)
M = male; F = female; AA = aplastic anemia; PNH = paroxysmal nocturnal 
hemoglobinuria; ALL = acute lymphoblastic leukemia; AML = acute myeloid 
leukemia; CML = chronic myeloid leukemia; CMML = chronic myelomonocytic 
leukemia; MDS = myelodysplastic syndrome.
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P values were corrected by means of Bonferroni’s correction. The 
P value was multiplied by the number of comparisons made. The 
resulting corrected Pc < 0.05 was accepted as significant. Cumula-
tive incidences were calculated for acute and chronic GVHD.
RESULTS
Patients and donors
The patients were 108 men and 68 women with a median age of 34 
years (range: 1-60 years) and the donors were 90 men and 86 women 
with a median age of 32 years (range: 1-62 years). The condition-
ing therapy, GVHD prophylaxis, GVHD treatment, transplantation 
procedures and clinical support have been described elsewhere.16,17
Occurrence of acute and chronic GVHD
In total, 150 patients showed no evidence of acute GVHD or 
developed acute GVHD grade I; 11 (42.3%) had grade II; 11 
(42.3%) had grade III; and 4 (15.4%) had grade IV. The cumula-
tive occurrence of acute GVHD of grades II-IV was 14.8%. A total 
of 140 patients were evaluated for chronic GVHD: 22 (15.7%) 
developed the limited and 58 (41.4%) the extensive clinical form. 
The cumulative occurrence of chronic GVHD was 57.1%.
Frequency of HLA variants in GVHD
The frequencies of the HLA class I and II variants in patients who 
received a HSCT are shown in Figure 1. By cross-tabulating each 
HLA variant with the occurrence of GVHD, ten variants were 
found to be associated with either the presence or the absence 
of GVHD with P < 0.05. These HLA variants were A2, A9, A10, 
A23, A26, B16, B53, B55, DRB1*15 and DQB1*05, as shown in 
Tables 2 and 3. After Bonferroni’s correction, the HLA-A10, 
-A26 and -B55 variants remained statistically significant.
Figure 1. Human leukocyte antigen (HLA)-A, -B, -DRB1 and -DQB1 
allele frequencies among 176 hematopoietic stem-cell transplant 
































































































































































































































































































































































































































































































































grades II-IV (%) P OR 95% CI
n = 150 n = 26
A10 7 2.3 7 13.5 0.0007 6.51 2.18-19.44
A26 5 1.7 6 11.5 0.0020 7.70 2.26-26.25
B16 23 7.7 0 0.0 0.0333 0.12 0.01-1.96
B55 2 0.7 5 9.6 0.0010 15.85 2.99-84.07
DRB1*15 25 8.6 9 21.4 0.0211 2.91 1.25-6.77
DQB1*05 38 15.2 12 30.0 0.0380 2.39 1.12-5.11
Table 2. Association between human leukocyte antigen (HLA) alleles and acute graft-versus-host disease (aGVHD)







presence (%) P OR 95% CI
n = 58 n = 82
A2 41 35.3 31 18.9 0.0031 0.43 0.25-0.74
A9 10 8.6 34 20.7 0.0100 2.77 1.31-5.87
A23 1 0.9 10 6.1 0.0292 7.47 0.94-59.17
B53 5 4.3 0 0.0 0.0116 0.07 0.0-1.25
Table 3. Association between human leukocyte antigen (HLA) alleles and chronic graft-versus-host disease (cGVHD)
n = number of alleles; P = probability; OR = odds ratio; CI = confidence interval.
 ORIGINAL ARTICLE | Cardozo DM, Lieber SR, Marques SBD, Aranha FJ, Vigorito AC, Souza CA, Visentainer JEL






grades III-IV (%) P OR 95% CI
n = 161 n = 15
B35 30 9.3 7 23.3 0.0373 2.96 1.17-7.48
B49 4 1.2 3 10.0 0.0155 8.33 1.88-41.52
B55 4 1.2 4 13.3 0.0024 12.23 2.89-51.75
Table 4. Results from analysis on severe (grades III–IV) acute graft-versus-host disease (aGVHD)







extensive (%) P OR 95% CI
n = 80 n = 60
A2 51 31.9 21 17.5 0.0097 0.45 0.25-0.81
A9 14 8.8 30 25.0 0.0004 3.48 1. 57-6.91
A24 11 6.9 22 18.3 0.0059 3.04 1.41-6.55
A26 2 1.3 7 5.8 0.0411 4.89 1.00-24.00
Table 5. Results from analysis on severe (extensive) chronic graft-versus-host disease (cGVHD)
n = number of alleles; P = probability; OR = odds ratio; CI = confidence interval.
Frequency of HLA variants in acute and chronic GVHD
Table 2 shows the significant frequencies of HLA associ-
ated with acute GVHD. Acute GVHD (grades 0-I) was pos-
itively associated with HLA-A10 (P = 0.0007; Pc = 0.0133), 
HLA-A26 (P = 0.002; Pc = 0.038), B55 (P = 0.001; Pc = 0.033), 
DRB1*15 (P = 0.0211; Pc = 0.2743) and DQB1*05 (P = 0.038; 
Pc  =  0.19). HLA-B16 was more frequent in patients who 
did not develop acute GVHD (grades 0-I), but this differ-
ence did not remain significant after Bonferroni’s correction 
(P = 0.0333; Pc = 1.099).
Chronic GVHD was positively associated with HLA-A9 
(P = 0.01; Pc = 0.19) and A23 (P = 0.0292; Pc = 0.5548), and neg-
atively with A2 (P = 0.0031; Pc = 0.0589) and B53 (P = 0.0116; 
Pc = 0.3828).
Frequency of HLA variants in severe acute and chronic 
GVHD 
Table 4 compares the frequencies of HLA in relation to 
severe acute GVHD. It shows that the HLA-B35 (P = 0.0373; 
Pc = 1.2309), B49 (P = 0.0155; Pc = 0.5115) and B55 (P = 0.0024; 
Pc = 0.0792) variants were higher in patients with acute GVHD 
grade 3 or above, than in other patients.
In patients with extensive chronic GVHD, the HLA-A9 
(P  =  0.0004; Pc = 0.0076), A24 (P = 0.0059; Pc = 0.1121) and 
A26 (P = 0.0411; Pc = 0.7809) variants were higher than in other 
patients, as shown in Table 5. HLA-A2 was lower in these patients 
(P = 0.0097; Pc = 0.1843). 
DISCUSSION
Many studies have analyzed risk factors for GVHD in relation to 
HLA, cytokines, killer immunoglobulin-like receptors (KIR) and 
other variants.3-11,18-24
Our analysis investigated the role of class I and II HLA vari-
ants on GVHD development in a population of 176 patients, 
and suggests that these were determinants for acute and chronic 
GVHD in allogenic HSCT patients with an HLA-identical sib-
ling donor. HLA-A26 (a split of HLA-A10) was associated 
with higher risk of acute GVHD, in agreement with previous 
studies.3,5,7,9,11
According to Bross et al.,8 HLA-A19 and B17 were associated 
with a lower risk of acute GVHD, whereas HLA-Cw4, A-11 and 
B21 appeared to be associated with a higher risk. Our data were 
concordant with this, showing an association between HLA-B49 
(a split of HLA-B21) and severe acute GVHD. However, HLA-B35 
was associated with a higher risk of severe acute GVHD, in con-
trast with the findings of Storb et al. and Ghavamzadeh et al.5,10
We did not find any correlation between acute GVHD risk 
and HLA-A3 and A11, in contrast with the findings of Clark 
et al. and Bross et al., respectively;6,8 and likewise in relation to 
HLA-DR16 and DR3.7
While the present study showed that HLA-DRB1*15 and 
DQB1*05 (one of the alleles in linkage disequilibrium with DRB1*15) 
were higher in patients with acute GVHD (grades II to IV), Batti-
walla et al. identified absence of HLA-DR15 as a factor significantly 
associated with acute GVHD.4 However, there is a hypothesis that 
immunodominant myeloid antigens are preferentially presented by 
HLA-DR15, thus suggesting that this allele has an important role in 
relation to acute GVHD development.
Several factors could explain these differential results, includ-
ing patients who received transplants from unrelated donors and 
the use of serological typing methods in a subgroup of patients, 
whereas all individuals in our cohort received transplants from 
HLA-identical siblings and were typed as HLA class II using 
molecular methods. It is worth noting that our study has an 
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important limitation regarding clinical application, due to the 
statistical method used.
Moreover, Stern et al. reported that DRB1*15 showed an asso-
ciation with lower disease relapse and greater survival in patients 
treated with HSCT for leukemia or non-Hodgkin lymphoma, but 
they did not observe any significant difference regarding the inci-
dence of acute GVHD.12 In our view, DRB1*15 could reduce the 
graft-versus-leukemia effect after HSCT, thereby increasing the 
incidence of GVHD.
Our study also suggested that other HLA antigens were asso-
ciated with acute GVHD, such as HLA-B16 (protection factor) 
and B55 (susceptibility factor), which were also associated with 
GVHD severity. 
This study found statistically significant differences in the 
occurrence and severity of chronic GVHD. HLA-A9 (A23 or A24) 
was positively associated with both of them, while HLA-A2 was 
associated with protection. HLA-B53 was associated with chronic 
GVHD development, but not with the severe (extensive) form, 
while HLA-A26 was associated with extensive chronic GVHD. 
Although HLA-A26 has been associated with acute GVHD and 
severe chronic GVHD, the immunopathogenesis of these GVHD 
forms are different, which could explain the different associations 
observed with the forms of disease.
Few studies have investigated an association between 
HLA and chronic GVHD. Remberger et al. found that HLA-
B27 was associated with a lower risk of developing chronic 
GVHD.9 According to Battiwalla et al., there was no signifi-
cant difference in the two groups, regarding chronic GVHD 
incidence or severity.4
The differences between various HLA variants and their cor-
relations with the risk of GVHD in different centers and coun-
tries may be due to differences in ethnicity between populations. 
In addition to these differences, we emphasize that our study had 
limitations relating to its design and the number of patients.
CONCLUSION
These results show that MHC variants may influence the occur-
rence of GVHD in HSCT with HLA-identical sibling donors. 
However, we suggest that collaborative studies using larger cen-
tral registry datasets should be conducted in order to explore clin-
ical outcomes according to HLA antigen status in HLA-matched 
allogenic stem cell transplantation.
REFERENCES
1. Dickinson AM, Charron D. Non-HLA immunogenetics in hematopoietic 
stem cell transplantation. Curr Opin Immunol. 2005;17(5):517-25.
2. Charron D. Immunogenetics today: HLA, MHC and much more. Curr 
Opin Immunol. 2005;17(5):493-7.
3. Mohyeddin Bonab M, Alimoghaddam K, Vatandoust S, et al. Are 
HLA antigens a risk factor for acute GVHD in thalassemic patients 
receiving HLA-identical stem cell transplantation? Transplant Proc. 
2004;36(10):3190-3.
4. Battiwalla M, Hahn T, Radovic M, et al. Human leukocyte antigen 
(HLA) DR15 is associated with reduced incidence of acute GVHD 
in HLA-matched allogeneic transplantation but does not impact 
chronic GVHD incidence. Blood. 2006;107(5):1970-3.
5. Storb R, Prentice RL, Hansen JA, Thomas ED. Association between 
HLA-B antigens and acute graft-versus-host disease. Lancet. 
1983;2(8354):816-9.
6. Clark RE, Hermans J, Madrigal A, et al. HLA-A3 increases and HLA-
DR1 decreases the risk of acute graft-versus-host disease after 
HLA-matched sibling bone marrow transplantation for chronic 
myelogenous leukaemia. Br J Haematol. 2001;114(1):36-41.
7. Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-
host disease in histocompatible donor bone marrow transplantation. 
Transplantation. 1991;51(6):1197-203.
8. Bross DS, Tutschka PJ, Farmer ER, et al. Predictive factors for acute 
graft-versus-host disease in patients transplanted with HLA-identical 
bone marrow. Blood. 1984;63(6):1265-70.
9. Remberger M, Persson U, Hauzenberger D, Ringdén O. An association 
between human leucocyte antigen alleles and acute and chronic 
graft-versus-host disease after allogeneic haematopoietic stem cell 
transplantation. Br J Haematol. 2002;119(3):751-9.
10. Ghavamzadeh A, Alimoghaddam K, Behrouzan O, et al. HLA and 
risk of acute graft versus host disease in allogenic bone marrow 
transplantation from an HLA-identical sibling. Arch Irn Med. 
2002;5(1):16-20. Available from: http://www.ams.ac.ir/AIM/0251/
aim025116.htm. Accessed in 2011 (Nov 22).
11. Adams KM, Holmberg LA, Leisenring W, et al. Risk factors for 
syngeneic graft-versus-host disease after adult hematopoietic cell 
transplantation. Blood. 2004;104(6):1894-7. 
12. Stern M, Passweg J, Tiercy JM, et al. Human leukocyte antigen DR15 
is associated with reduced relapse rate and improved survival after 
human leukocyte antigen-identical sibling hematopoietic stem cell 
transplantation. Biol Blood Marrow Transplant. 2006;12(11):1169-75. 
13. Petersdorf EW, Malkki M. Genetics of risk factors for graft-versus-host 
disease. Semin Hematol. 2006;43(1):11-23.
14. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-
versus-host disease in human recipients of marrow from HL-A-
matched sibling donors. Transplantation. 1974;18(4):295-304.
15. Atkinson K, Horowitz MM, Gale RP, et al. Consensus among bone 
marrow transplanters for diagnosis, grading and treatment of 
chronic graft-versus-host disease. Committee of the International 
Bone Marrow Transplant Registry. Bone Marrow Transplant. 
1989;4(3):247-54.
16. Visentainer JE, Lieber SR, Persoli LB, et al. Serum cytokine levels and 
acute graft-versus-host disease after HLA-identical hematopoietic 
stem cell transplantation. Exp Hematol. 2003;31(11):1044-50.
17. Vigorito AC, Azevedo WM, Marques JF, et al. A randomised, prospective 
comparison of allogeneic bone marrow and peripheral blood 
 ORIGINAL ARTICLE | Cardozo DM, Lieber SR, Marques SBD, Aranha FJ, Vigorito AC, Souza CA, Visentainer JEL
224     Sao Paulo Med J. 2012; 130(4):219-24
progenitor cell transplantation in the treatment of haematological 
malignancies. Bone Marrow Transplant. 1998;22(12):1145-51.
18. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-
10 promoter polymorphism to graft-versus-host disease and 
survival after hematopoietic-cell transplantation. N Engl J Med. 
2003;349(23):2201-10.
19. Laguila Visentainer JE, Lieber SR, Lopes Persoli LB, et al. Relationship 
between cytokine gene polymorphisms and graft-versus-host 
disease after allogeneic stem cell transplantation in a Brazilian 
population. Cytokine. 2005;32(3-4):171-7.
20. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-
identical sibling hematopoietic stem-cell transplantation for acute 
myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 
2005;105(12):4878-84.
21. Viel DO, Tsuneto LT, Sossai CR, et al. IL2 and TNFA gene polymorphisms 
and the risk of graft-versus-host disease after allogeneic 
haematopoietic stem cell transplantation. Scand J Immunol. 
2007;66(6):703-10.
22. Azarpira N, Ramzi M, Aghdaie MH, Darai M, Geramizadeh B. Interleukin-
10 gene polymorphism in bone marrow transplant recipients. Exp 
Clin Transplant. 2008;6(1):74-9.
23. Schellekens J, Rozemuller EH, Petersen EJ, et al. Activating KIRs exert a 
crucial role on relapse and overall survival after HLA-identical sibling 
transplantation. Mol Immunol. 2008;45(8):2255-61.
24. Visentainer JEL, Sell AM, Franceschi DA, Lieber SR, Souza CA. 
Importância de polimorfismos de genes reguladores de citocinas em 
transplantes de células progenitoras hematopoiéticas [Importance of 
regulatory cytokine gene polymorphisms in hematopoietic stem cell 
transplantation]. RBCF Rev Bras Ciênc Farm (Impr). 2008;44(4):739-48.
Acknowledgements: We would like to thank the staff and friends of the 
HLA Laboratory of Universidade Estadual de Campinas (Unicamp) who 
contributed to this work
Sources of funding: None  
Conflict of interest: None
Date of the first submission: January 21, 2010 
Last received: December 13, 2011 
Accepted: December 19, 2011
Address for correspondence:  
Jeane Eliete Laguila Visentainer 
Av. Colombo, 5.790, Zona 07  
Maringá (PR) — Brasil  
CEP 87020-900 
Tel. (+55 44) 3011-4864 
Fax. (+55 44) 3011-4931 
E-mail: jelvisentainer@gmail.com 
E-mail: jelvisentainer@uem.br
